4//SEC Filing
Adaptimmune Therapeutics PLC 4
Accession 0001104659-17-002826
$ADAPCIK 0001621227operating
Filed
Jan 17, 7:00 PM ET
Accepted
Jan 18, 5:02 PM ET
Size
5.8 KB
Accession
0001104659-17-002826
Insider Transaction Report
Form 4
Binder-Scholl Gwendolyn Knowlton
EVP, Adaptimmune LLC
Transactions
- Award
Option to purchase Ordinary Shares
2017-01-13+2,072,976→ 2,072,976 totalExercise: $0.72Exp: 2027-01-13→ Ordinary Shares (2,072,976 underlying)
Footnotes (2)
- [F1]The exercise price was converted from GBP0.59 based on the closing midpoint exchange rate for the U.S. dollar on the day prior to the date of grant listed in the Financial Times. The actual exercise price will be the pounds sterling amount.
- [F2]Exercisable as to 518,244 Ordinary Shares on January 13, 2018 and will be exercisable as to the remainder in monthly installments of 43,187 Ordinary Shares on the thirteenth of each month from February 13, 2018 through January 13, 2021.
Documents
Issuer
Adaptimmune Therapeutics PLC
CIK 0001621227
Entity typeoperating
IncorporatedUnited Kingdom
Related Parties
1- filerCIK 0001621227
Filing Metadata
- Form type
- 4
- Filed
- Jan 17, 7:00 PM ET
- Accepted
- Jan 18, 5:02 PM ET
- Size
- 5.8 KB